Enteric Oxalate Absorption Study in Unclassified Hyperoxaluria
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00588120|
Recruitment Status : Active, not recruiting
First Posted : January 8, 2008
Last Update Posted : June 19, 2017
|Condition or disease||Intervention/treatment||Phase|
|Enteric Hyperoxaluria Hyperoxaluria||Drug: C-13 labeled oxalate||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||125 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Investigations Into the Genotype and Phenotype of Unclassified Hyperoxaluria: Enteric Oxalate Absorption Study|
|Study Start Date :||December 1998|
|Estimated Primary Completion Date :||November 2018|
|Estimated Study Completion Date :||November 2018|
Experimental: C-13 labeled oxalate
Drug: C-13 labeled oxalate
A single prescribed dose of C-13 labeled oxalate will be given orally in capsule form or in jello. Urine will be collected for 24 hours after the dose.
Take one capsule by mouth for one day.
Other Name: oxalate
- Urine oxalate measured following absorption of oral oxalate dose [ Time Frame: 2 years ]Subjects with hyperoxaluria will be given an oral test dose of oxalate, with measurement of urine oxalate excretion over the next 24 hours.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00588120
|United States, Minnesota|
|Mayo Clinic Rochester|
|Rochester, Minnesota, United States, 55905|
|Principal Investigator:||Dawn Milliner||Mayo Clinic|